LRP5 and Insulin resistance: Compared to controls, GoF LRP5 mutation carriers exhibited lower fasting glucose, fasting insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), HOMA of β-cell function (HOMA-B), and adipose tissue insulin resistance (Adipo-IR).